lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Efficacy and Safety of Oral Janus Kinase Inhibitors for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

47 Pages Posted: 20 Feb 2019

See all articles by Christopher Ma

Christopher Ma

University of Calgary - Division of Gastroenterology & Hepatology; Robarts Clinical Trials, Inc.

Jeffrey K. Lee

Kaiser Permanente

Anish R. Mitra

University of British Columbia (UBC)

Anouar Teriaky

University of California San Diego

Daksh Choudhary

University of Calgary

Tran M. Nguyen

Robarts Clinical Trials, Inc.

Niels Vande Casteele

University of California San Diego

Reena Khanna

Western University

Remo Panaccione

University of Calgary

Brian G. Feagan

Robarts Clinical Trials, Inc.; Western University

Vipul Jairath

Robarts Clinical Trials, Inc.; Western University

More...

Abstract

Background: Janus kinase (JAK) inhibitors are novel agents for treatment of inflammatory bowel disease. We aimed to determine the efficacy and safety of Janus kinase (JAK) inhibitors for the treatment of Crohn's disease (CD) and ulcerative colitis (UC).

Methods: A systematic review and meta-analysis were conducted. PubMed, Embase, and CENTRAL were searched to November 1, 2018 for randomized placebo-controlled trials (RCTs) of JAK inhibitors in adult patients with CD or UC. Clinical, endoscopic, and safety outcomes were extracted and rates relative to placebo were pooled using a random-effects model.

Findings: A total of 12 RCTs (5 CD, 7 UC) were included. Patients were randomized to placebo (n=844), tofacitinib (n=1,882), filgotinib (n=130), peficitinib (n=176), upadacitinib (n=387), or TD-1473 (n=31). JAK inhibitor treatment was associated with induction of clinical remission in CD (relative risk RR 1∙38 [95% confidence interval CI 1∙04-1∙83], p=0 ∙025, I2=14%) and UC (RR 3∙07 [95% CI: 2∙03-4∙63], p<0∙001, I2=0%). In UC, JAK inhibitor treatment was associated with induction of endoscopic remission (endoscopic Mayo subscore MCSe=0/1) (RR 2∙43 [95% CI: 1∙64- 3∙59], p<0∙001, I2=27%) and mucosal healing (MCSe=0) (RR 5∙50 [95% CI: 2∙46-12∙32], p<0∙001, I2=0%). JAK inhibitor treatment increased the risk of infection compared to placebo (RR 1∙40 [95% CI: 1∙18-1∙67], p<0∙001, I2=0%), particularly for herpes zoster. All studies were rated as low or unclear risk of bias.

Interpretation: JAK inhibitors are effective for induction of clinical and endoscopic remission in CD and UC, although are associated with an increased risk of infectious complications.

Funding Statement: There was no funding source for this study. Christopher Ma is supported by a Clinician Fellowship from the Canadian Institutes of Health Research and the Canadian Association of Gastroenterology. Niels Vande Casteele is supported by a Research Scholar Award from the American Gastroenterological Association.

Declaration of Interests: Christopher Ma, Jeffrey Lee, Anish Mitra, Anouar Teriaky, and Daksh Choudhary have no conflicts of interest to disclose.

Tran Nguyen is an employee of Robarts Clinical Trials, Inc.

Niels Vande Casteele has received research support from R-Biopharm and Takeda and consulting fees from Janssen, Pfizer, Progenity, Prometheus, Takeda, and UCB.

Reena Khanna has received consulting/speaker fees from AbbVie, Encycle, Janssen, Merck, Pendopharm, Pfizer, Roche, Robarts Clinical Trials, Shire, and Takeda Canada.

Remo Panaccione has received scientific advisory board fees from Abbott/AbbVie, Amgen, Janssen, Merck, Pfizer, Prometheus Laboratories, Salix Pharma, Shire, Takeda, and Warner Chilcott, consulting fees from Abbott/AbbVie, Amgen, Aptalis, Astra Zeneca, Baxter, BMS, Centocor, Elan/Biogen, Eisai, Ferring, GSK, Janssen, Merck, Millennium, Pfizer, Proctor & Gamble, Prometheus Therapeutics and Diagnostics, Schering-Plough, Shire, Takeda, UCB Pharma, and Warner Chilcott, research grants from Abbott/AbbVie, Amgen, Aptalis, Astra Zeneca, Baxter, BMS, Centocor, Eisai, Elan/Biogen, Ferring, GSK, Janssen, Merck, Millennium, Pfizer, Proctor & Gamble, Prometheus, Shire, Schering-Plough, Takeda, UCB Pharma, and Warner Chilcott, and speaker’s bureau fees from Abbott/AbbVie, Amgen, Aptalis, Astra Zeneca, Baxter, BMS, Centocor, Eisai, Elan/Biogen, Ferring, GSK, Janssen, Merck, Millennium, Pfizer, Proctor & Gamble, Prometheus, Schering-Plough, Shire, Takeda, UCB Pharma, and Warner Chilcott.

Brian Feagan has received grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor Inc., Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix, and Wyeth Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, Centocor Inc., Elan/Biogen, Janssen440 Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix Pharmaceuticals, Novonordisk, GSK, Actogenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma Inc., and Sigmoid Pharma; and speaker’s fees from UCB, AbbVie, and J&J/Janssen.

Vipul Jairath has received consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena pharmaceuticals, Genetech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Robarts Clinical Trials, Topivert, Celltrion; speaker’s fees from Takeda, Janssen, Shire, Ferring, Abbvie, Pfizer

Ethics Approval Statement: PRISMA guidelines referenced.

Keywords: Crohn's disease; ulcerative colitis; Janus kinase; oral small molecule

Suggested Citation

Ma, Christopher and Lee, Jeffrey K. and Mitra, Anish R. and Teriaky, Anouar and Choudhary, Daksh and Nguyen, Tran M. and Casteele, Niels Vande and Khanna, Reena and Panaccione, Remo and Feagan, Brian G. and Jairath, Vipul, Efficacy and Safety of Oral Janus Kinase Inhibitors for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (August 2, 2019). Available at SSRN: https://ssrn.com/abstract=3335055

Christopher Ma (Contact Author)

University of Calgary - Division of Gastroenterology & Hepatology ( email )

Canada

Robarts Clinical Trials, Inc. ( email )

Canada

Jeffrey K. Lee

Kaiser Permanente

CA
United States

Anish R. Mitra

University of British Columbia (UBC)

2329 West Mall
Vancouver, British Columbia BC V6T 1Z4
Canada

Anouar Teriaky

University of California San Diego

9500 Gilman Drive
La Jolla, CA 92093
United States

Daksh Choudhary

University of Calgary

University Drive
Calgary, Alberta T2N 1N4
Canada

Tran M. Nguyen

Robarts Clinical Trials, Inc.

Canada

Niels Vande Casteele

University of California San Diego

9500 Gilman Drive
La Jolla, CA 92093
United States

Reena Khanna

Western University

1151 Richmond St
London, Ontario N6A 3K7
Canada

Remo Panaccione

University of Calgary

University Drive
Calgary, Alberta T2N 1N4
Canada

Brian G. Feagan

Robarts Clinical Trials, Inc.

Canada

Western University

1151 Richmond St
London, Ontario N6A 3K7
Canada

Vipul Jairath

Robarts Clinical Trials, Inc.

Canada

Western University

1151 Richmond St
London, Ontario N6A 3K7
Canada

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
85
Downloads
15